Access Vascular’s HydroPICC and HydroMid Catheters Show Reduced Complication Rates in Early Results

September 20, 2021—Access Vascular, Inc. (AVI) announced initial findings from two new clinical studies that demonstrate a significant reduction in complications when using AVI’s hydrophilic materials for peripherally inserted central catheters (PICCs) and midline catheters.

According to the company, these early findings highlight the potential for AVI’s HydroPICC and HydroMid catheters, which are made from consistently hydrophilic material that is designed to mimic the body’s natural chemistry and reduce both intraluminal and extraluminal complications in vascular access and other applications.

The findings were presented at AVA 2021, the Association for Vascular Access annual scientific meeting held virtually September 16-19.

The company stated that the first retrospective clinical study compared complication rates such as occlusions and replacements in 61 standard PICCs and 60 HydroPICCs, respectively. The study found a statistically significant reduction in complication rates for the HydroPICC group.

The second retrospective study compared complication rates of occlusions, replacements, deep vein thrombosis (DVT), and phlebitis in 100 standard midline catheters and 100 HydroMid catheters. The interim data analysis indicates significantly lower DVT and phlebitis rates in the HydroMid group compared to the standard group. In addition, the total failure rate in the HydroMid group was significantly lower than in the standard group.

Joe Bunch, RN, Chief Executive Officer of ProVasc Solutions LTD in Romeoville, Illinois, serves as Principal Ivestigator for both studies. He commented in the company’s press release, “As a clinician, my mission is to deliver the best possible experience to my patients. These studies confirmed my real-world experience with AVI catheters—there are simply no escalations on these lines. That means better patient outcomes and less risk.”

In March 2021, AVI announced it has closed on a Series B round of financing to generate postmarket data on the company’s two commercial venous access devices as well as to expand its portfolio of devices and commercialize the portfolio of products. In February 2021, the company announced FDA clearance of the HydroMid device, which is a 4-F, single-lumen midline catheter with a maximum usable length of 20 cm. In March 2020, the company announced FDA clearance for the second generation of its HydroPICC device.